Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients-Reference-Cited by-同舟云学术

Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients

Published:2018-09 Issue:9 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Roch Melanie¹,Varela Maria Celeste¹,Taglialegna Agustina¹,Rose Warren E.²,Rosato Adriana E.¹

Affiliation:

1. Department of Pathology and Genomic Medicine, Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute, Houston, Texas, USA

2. School of Pharmacy, University of Wisconsin—Madison, Madison, Wisconsin, USA

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) acquisition in cystic fibrosis (CF) patients confers a clinical outcome worse than that in non-CF patients with an increased rate of declined lung function. Telavancin, an approved lipoglycopeptide used to treat infections due to S. aureus , has a dual mode of action causing inhibition of peptidoglycan synthesis and membrane depolarization.

Funder

Theravance R&D

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00956-18

Reference27 articles.

1. Recruitment of penicillin-binding protein PBP2 to the division site of Staphylococcus aureus is dependent on its transpeptidation substrates

2. The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry

3. Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis